aibioJupiter Neurosciences gets Nasdaq minimum bid price deficiency notice
Tickers JUNS
Jupiter Neurosciences received a Nasdaq letter on March 21, 2025 saying its stock fails the $1.00 minimum bid price rule. The company has until September 17, 2025 to regain compliance.
Key facts
- Company
- Jupiter Neurosciences, Inc. (NASDAQ: JUNS)
- News type
- Listings
- Primary source
- JUPITER NEUROSCIENCES, INC. Form 8-K filed March 25, 2025 (SEC EDGAR)
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) says Nasdaq has told it that its common stock no longer meets the exchange's minimum bid price requirement. The company reported the Nasdaq deficiency notice in a Form 8-K filed March 25, 2025, under Item 3.01. That item covers a notice of delisting or failure to satisfy a continued listing rule or standard.
The shares keep trading for now. The company says receipt of the notice has no immediate effect on the listing of its shares, which continue to trade uninterrupted on Nasdaq under the ticker "JUNS".
What the Nasdaq notice says
Jupiter Neurosciences received a letter from the Nasdaq Stock Market LLC on March 21, 2025. It says Jupiter Neurosciences is not in compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing. The rule requires a company to maintain a minimum bid price of $1.00 per share for its listed securities. A bid price is the price a buyer is willing to pay for a share.
A shortfall counts as a failure only after it lasts. Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The filing cites the closing bid price of the company's shares for the 30 consecutive business days before the notice, from February 6, 2025 through March 20, 2025. On that basis, the company says, it no longer meets the requirement.
The 180-day compliance period
The notice is a warning, not a delisting. Under the same rule, Nasdaq gave the company 180 calendar days, or until September 17, 2025, to regain compliance with Listing Rule 5550(a)(2).
The filing describes how the company can regain compliance during that period. The bid price of its common stock has to be at least $1.00 for a minimum period of 10 consecutive days. If that does not happen by September 17, 2025, the filing says the company "may be eligible for additional time to regain compliance or may face delisting." Delisting means the shares would no longer trade on the exchange.
Two separate clocks are at work. The first, 30 consecutive business days of a deficient bid price, has already run and produced the notice. The second is the 180-day window, which ends on September 17, 2025.
What the company says it will do
Jupiter Neurosciences says it intends to monitor the closing price of its common stock and may, if appropriate, consider available options to regain compliance with the minimum bid price requirement.
The company also cautions that there can be no assurances that it will be able to regain compliance with the minimum bid price requirement or maintain compliance with the other Nasdaq listing requirements. The warning therefore covers two things: the bid price itself and the exchange's other continued listing requirements.
Who signed the filing
Chief Executive Officer Christer Rosén signed the Form 8-K on March 25, 2025, on behalf of Jupiter Neurosciences, Inc. Besides the Item 3.01 disclosure, the report lists one exhibit under Item 9.01, the cover page interactive data file embedded in the filing. The letter itself came from the Nasdaq Stock Market LLC, which the filing calls NASDAQ.